Want to see CATX full AI Analyst Report?
CATX Stock Chart & Stats
$2.91
-$0.04(-1.36%)
At close: 4:00 PM EDT
$2.91
-$0.04(-1.36%)
Day’s Range― - ―
52-Week Range$1.96 - $6.16
Previous CloseN/A
Volume671.33K
Average Volume (3M)2.11M
Market Cap
$365.29M
Enterprise Value$178.51
Total Cash (Recent Filing)$236.88M
Total Debt (Recent Filing)$2.37M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Nov 17, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.43
Shares Outstanding114,151,665
10 Day Avg. Volume1,481,951
30 Day Avg. Volume2,113,515
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)0.98
Price to Sales (P/S)0.00
P/FCF Ratio-2.13
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$12.80Price Target Upside339.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-0.99
Revenue Forecast (FY)$389.88K
Bulls Say, Bears Say
Bulls Say
Low Leverage And Strengthened Equity BaseVery low debt and a materially larger equity base reduce near-term financial distress risk and give management flexibility to fund R&D, manufacturing buildout and trials without immediate refinancing. This balance-sheet strength supports execution through mid-term clinical milestones and partnership talks.
Vertically Integrated Manufacturing ExpansionExpanding regional production capacity and a four-site network creates durable operational advantages for radiopharmaceuticals: reliable supply, reduced logistics to hospitals, and potential cost efficiencies. This infrastructure supports commercialization scalability and is a structural barrier to entrants.
Progressing Lead Program Toward Phase 3Advancing a lead asset to Phase 3 is a material de-risking step versus early-stage programs. A clear registration path in SSTR2+ neuroendocrine tumors would create a durable revenue and partnership opportunity, validate the 212Pb platform, and underpin longer-term commercial strategy if successful.
Bears Say
Persistent Heavy Cash BurnSustained negative operating and free cash flows mean the company must continue to access external capital to fund trials and manufacturing. Ongoing burn increases dilution and limits strategic optionality; absent clinical or partnership milestones, financing dependence poses multi-quarter execution risk.
Minimal, Volatile Revenue And Large LossesThe company lacks meaningful commercial revenue and is generating persistent operating losses, signaling a cost structure well ahead of scale. Continued negative returns consume shareholder capital and constrain the firm's ability to self-fund late-stage development without dilution or licensing.
Binary Clinical And Regulatory Risk From Early-stage ProgramsPrograms remain in early development where trial outcomes, safety signals or regulatory delays are common. The company's prospects hinge on successful pivotal results and approvals; failures or setbacks would materially impair commercial prospects and prolong reliance on external funding.
Perspective Therapeutics News
CATX FAQ
What was Perspective Therapeutics, Inc.’s price range in the past 12 months?
Perspective Therapeutics, Inc. lowest stock price was $1.96 and its highest was $6.16 in the past 12 months.
What is Perspective Therapeutics, Inc.’s market cap?
Perspective Therapeutics, Inc.’s market cap is $365.29M.
When is Perspective Therapeutics, Inc.’s upcoming earnings report date?
Perspective Therapeutics, Inc.’s upcoming earnings report date is Nov 17, 2026 which is in 93 days.
How were Perspective Therapeutics, Inc.’s earnings last quarter?
Perspective Therapeutics, Inc. released its earnings results on Aug 10, 2026. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.251 by $0.031.
Is Perspective Therapeutics, Inc. overvalued?
According to Wall Street analysts Perspective Therapeutics, Inc.’s price is currently Undervalued.
Does Perspective Therapeutics, Inc. pay dividends?
Perspective Therapeutics, Inc. does not currently pay dividends.
What is Perspective Therapeutics, Inc.’s EPS estimate?
Perspective Therapeutics, Inc.’s EPS estimate is -0.25.
How many shares outstanding does Perspective Therapeutics, Inc. have?
Perspective Therapeutics, Inc. has 114,151,665 shares outstanding.
What happened to Perspective Therapeutics, Inc.’s price movement after its last earnings report?
Perspective Therapeutics, Inc. reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.251. Following the earnings report the stock price went up 6%.
Which hedge fund is a major shareholder of Perspective Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CATX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Perspective Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.80 (339.86% Upside)
$12.80 (339.86% Upside)
Blogger Sentiment
Bullish
CATX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 80.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.87%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
26.16%
Trailing 12-Months
Company Description
Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
CATX Stock 12 Month Forecast
Average Price Target
$12.80
▲(339.86% Upside)
Technical Analysis
Ownership Overview
1.63% Insiders
6.91% Mutual Funds
32.75% Other Institutional Investors
44.44% Public Companies and
Individual Investors